Efficacy and safety of nicotinamide in haemodialysis patients: The NICOREN study

Nephrology Dialysis Transplantation

Volumn 32, Issue 5, 2017, Pages 870-879

  Lenglet, Aurelie ^a,b   Liabeuf, Sophie ^a,b   El Esper, Najeh ^b   Brisset, Sandrine ^b   Mansour, Janette ^c   Lemaire Hurtel, Anne Sophie ^b   Mary, Aurelien ^a,b   Brazier, Michel ^a,b   Kamel, Said ^a,b   Mentaverri, Romuald ^a,b   Choukroun, Gabriel ^a,b   Fournier, Albert ^b   Massy, Ziad A ^d,e,f  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c centre hospitalier de Soissons   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

chronic kidney disease; haemodialysis; hyperphosphataemia; nicotinamide; phosphate binders

Indexed keywords

NICOTINAMIDE; PHOSPHORUS; SEVELAMER;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BACTERIAL ENDOCARDITIS; BRAIN ISCHEMIA; CHRONIC KIDNEY FAILURE; CONFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPTIC STATE; ERYSIPELAS; FAINTNESS; FEMALE; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOPTYSIS; HEMORRHAGIC SHOCK; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSIVE CRISIS; HYPOTENSION; KNEE OSTEOARTHRITIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECTUM HEMORRHAGE; SCIATICA; SEPSIS; SERRATIA INFECTION; SIDE EFFECT; SKIN NECROSIS; SUPERINFECTION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VOMITING; WOUND COMPLICATION; BLOOD; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; NIACINAMIDE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVELAMER;

EID: 85020189388     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw042     Document Type: Article

References (40)

1. Block GA. Control of serum phosphorus: Implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10: 741-747
2. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
3. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
4. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
5. Cannata-Andía JB, Martin KJ. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant 2016; 31: 541-547
6. Lenglet A, Liabeuf S, Guffroy P et al. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D 2013; 13: 165-173
7. Kempson SA, Colon-Otero G, Ou SY et al. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981; 67: 1347-1360
8. Eto N, Miyata Y, Ohno H et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20: 1378-1384
9. Katai K, Tanaka H, Tatsumi S et al. Nicotinamide inhibits sodiumdependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14: 1195-1201
10. Rutkowski B, Slominska E, Szolkiewicz M et al. N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin?. Kidney Int Suppl 2003; S19-S21
11. Slominska EM, Kowalik K, Smolenski RT et al. Accumulation of poly(ADPribose) polymerase inhibitors in children with chronic renal failure. Pediatr Nephrol 2006; 21: 800-806
12. Lin H-H, Liou H-H, Wu M-S et al. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology (Carlton) 2014; 19: 672-678
13. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
14. Bleskestad IH, Bergrem H, Hartmann A et al. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol 2012; 13: 49
15. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
16. Reilly AM, Gray AK, Moe SM et al. Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium. Bone 2014; 67: 139-144
17. Takahashi Y, Tanaka A, Nakamura T et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104
18. Cheng SC, Young DO, Huang Y et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J AmSoc Nephrol 2008; 3: 1131-1138
19. Young DO, Cheng SC, Delmez JA et al. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009; 29: 562-567
20. Shahbazian H, Zafar Mohtashami A, Ghorbani A et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: A double-blind randomized clinical trial. Nefrologia 2011; 31: 58-65
21. Vasantha J, Soundararajan P, Vanitharani N et al. Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol 2011; 21: 245-249
22. Chiu Y-W, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-1096
23. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 2005; 68: 2911-2912
24. Chen AC, Martin AJ, Choy B et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl JMed 2015; 373: 1618-1626
25. Rutkowski B, Rutkowski P, Słominska E et al. Cellular toxicity of nicotinamide metabolites. J RenNutr 2012; 22: 95-97
26. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCAmutation carriers. NEngl J Med 2009; 361: 123-134
27. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010; 376: 245-251
28. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010; 376: 235-244
29. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011; 161: 471-477.e2
30. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291
31. Trevor A, Katzung B, Masters SK. Trevor's Pharmacology. Examination and Board Review, 8th edn. Lange, Chapt, Mc Graw-Hill Education/Medical, 2007, p. 45
32. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-38
33. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203-212
34. Albers JJ, Slee A, O'Brien KD et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62: 1575-1579
35. AIM-HIGH Investigators, BodenWE, Probstfield JL et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New Engl J Med 2011; 365: 2255-2267
36. Yilmaz MI, Sonmez A, Saglam M et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185
37. Oliveira RB, Cancela ALE, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010; 5: 286-291
38. Labonté ED, Carreras CW, Leadbetter MR et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol 2015; 26: 1138-1149
39. Rao M, Steffes M, Bostom A et al. Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol 2014; 39: 484-490
40. Isakova T, Ix JH, Sprague SM et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 2015; 26: 2328-233